Advanced/metastatic bladder cancer: current status and future directions

被引：44

作者：

Facchini, G. ^{[1
]}

Cavaliere, C. ^{[2
]}

Romis, L. ^{[3
]}

Mordente, S. ^{[3
]}

Facchini, S. ^{[4
]}

Iovane, G. ^{[5
]}

Capasso, M. ^{[5
]}

D'Errico, D. ^{[5
]}

Liguori, C. ^{[1
]}

Formato, R. ^{[1
]}

Cicala, S. ^{[1
]}

Andreozzi, F. ^{[6
]}

Di Lauro, G. ^{[3
]}

Imbimbo, C. ^{[4
]}

Vanni, M. ^{[7
]}

D'Aniello, C. ^{[8
]}

机构：

[1] ASL NA 2 Nord SM delle Grazie Hosp, UOC Med Oncol, Pozzuoli, NA, Italy

[2] ASL NA 3 Sud Osped Riuniti Area Nolana, UOC Med Oncol, Nola, NA, Italy

[3] ASL NA 2 Nord SM delle Grazie Hosp, UOC Urol, Pozzuoli, NA, Italy

[4] Univ Federico II Napoli, Dept Urol, Naples, Italy

[5] IRCCS Fdn G Pascale, Dept Unit Clin & Expt UroAndrol Oncol, Ist Nazl Tumori, Naples, Italy

[6] Univ Naples 2, Med Oncol, Naples, Italy

[7] Hlth Manager ASL NA 2 Nord, Naples, Italy

[8] AORN COLLI Osped Monaldi Cotugno CTO, Div Med Oncol, Naples, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2020年 / 24卷 / 22期

关键词：

Bladder cancer; Chemotherapy; Prognostic factors; Immunotherapy; METASTATIC UROTHELIAL CARCINOMA; TRANSITIONAL-CELL-CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; OPEN-LABEL; FACTOR RECEPTOR; DOUBLE-BLIND; COMPARING GEMCITABINE; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT;

D O I：

10.26355/eurrev_202011_23795

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In 2015 bladder cancer was the fourth most frequent malignancy and the eighth cause of death for cancer. At diagnosis, about 30% of bladder cancer (BC) patients present a muscle-invasive bladder cancer (MIBC) and 5% a metastatic bladder carcinoma (MBC). For fit MBC patients, combination chemotherapy (CC) is the standard of care for first-line treatment. CC includes both the treatment with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) either the classical or the dose-dense MVAC regimen, and the doublet therapy with cisplatin and gemcitabine (CG). Median progression free survival (PFS) was 7 months and median overall survival (OS) was 15 months. The present review provides an update on the management of MBC, with focus on target therapies, immune checkpoint inhibition, looking for prognostic and predictive factors.

引用

页码：11536 / 11552

页数：17

共 95 条

[1]

[Anonymous], 2014, WORLD CANCER RESEARCH JOURNAL, V1, P211

[2]

[Anonymous], 2012, ESMO C

[3]

[Anonymous], 2018, WCRJ

[4]

[Anonymous], 2015, J CLIN ONCOL S

[5]

[Anonymous], 2018, WCRJ

[6]

[Anonymous], 2018, WCRJ

[7]

[Anonymous], 2017, NCCN Clinical Practice Guidelines in Oncology

[8]

Apolo A, 2016, J CLIN ONCOL S, V34, P4534

[9]

Apolo AB, 2014, J CLIN ONCOL, V32

[10] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

← 1 2 3 4 5 6 7 8 9 10 →